Skip to Main Content

Paper Details

Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Med
12
2022
BA, COVID-19, K18, Omicron, Omicron BA.1, R346K, SARS, SARS-CoV-2, SARS-CoV-2 spike domains, STI-9167, cGMP, cGMP cell line, hACE2, human, human IgG1 LALA antibody, mice, severe acute respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus 2
Author NameAffiliation
Soner YildizIcahn School of Medicine, USA Global Health and Emerging Pathogens Institute
Lisa MiorinIcahn School of Medicine, USA Global Health and Emerging Pathogens Institute
Ignacio MenaIcahn School of Medicine
Raveen RathnasingheIcahn School of Medicine, Icahn School of Medicine at Mount Sinai
Viviana SimonIcahn School of Medicine, USA Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai
Emilia Mia SordilloIcahn School of Medicine at Mount Sinai
Harm van BakelIcahn School of Medicine
Harm van BakelIcahn School of Medicine
Michael SchotsaertIcahn School of Medicine, USA Global Health and Emerging Pathogens Institute
Adolfo Garc??a-SastreIcahn School of Medicine, USA Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, USA The Tisch Cancer Institute
Benhur LeeIcahn School of Medicine
Benhur LeeIcahn School of Medicine
Domenico TortorellaIcahn School of Medicine, USA Center for Therapeutic Antibody Development, Drug Discovery Institute
  • 1 - 13

Datasets

Release 1.2